I was reading through some articles this weekend, when I found one from BusinessWeek, questioning the viability of herbicide producer Monsanto Co. (NYSE: MON).

The article focuses on the past six months, a period when MON shares have lagged behind the broader market, and then wonders if the stock is still a viable long-term investment. The story was prompted by last Thursday's earnings forecast for $3.10 to $3.30 per share in fiscal 2010, which was well short of the $4.10 that the Street expects.

"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.